SINOVAC Secures Strategic 10-Year Vaccine Partnership in Brazil Through National PDP Framework

SÃO PAULO, Nov. 25, 2025 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has entered into a long-term strategic cooperation with the Brazilian Ministry of Health through two Productive Development Partnership (PDP) projects. The agreement, signed on November 24th, marks the first time a Chinese vaccine company has been integrated into Brazil's PDP framework.

Under the ten-year agreement, SINOVAC will collaborate with local partners, including the Tecpar Institute and Eurofarma, to establish a localized vaccine industry platform. The partnership involves a total supply of approximately 60 million doses of varicella and rabies vaccines, with a contract value exceeding USD 700 million the most significant international long-term supply agreement in the Company's history.

This cooperation aligns with broader bilateral public health initiatives and follows high-level institutional engagements. The signing ceremony, held at the Albert Einstein Hospital in São Paulo, was attended by senior officials including Minister of Health Alexandre Padilha, Minister of Science, Technology and Innovation Luciana Santos, and representatives from the Pan American Health Organization (PAHO) and the Brazilian Health Regulatory Agency (ANVISA).

"SINOVAC's mission is centered on contributing to resilient public health systems," stated Meng Weining, Vice President of SINOVAC. "This 10-year commitment is intended to address Brazil's national health priorities through reliable technology transfer and a stable supply of essential vaccines."

SINOVAC is set to expedite vaccine supply and localization initiatives in collaboration with Brazilian partners, establishing a specialized industrial platform. Beyond securing vaccine access within Brazil, the collaborative platform is designed to serve as a hub for supply resilience across emerging markets in the Global South.This partnership signifies a deepening of bilateral scientific cooperation, with plans to expand from vaccine production into broader biopharmaceutical research, intended to strengthen regional health infrastructure across Latin America.

About Brazil's PDP Program

The Productive Development Partnership (PDP) is a strategic initiative by the Brazilian government designed to systematically enhance national public health security. As a cornerstone of ongoing healthcare reforms, the program aims to reinforce the public health system through a comprehensive production strategy that ensures the stable supply of essential medicines. The core of the PDP framework involves collaboration with international pharmaceutical leaders possessing advanced technologies to establish localized manufacturing capabilities. Such partnership is intended to achieve self-sufficiency and secure the supply of critical health products within Brazil's Unified Health System (SUS).

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.